Study guide: Venous Thromboembolism Management

Course Outline

  1. Definition and Clinical Significance
  2. Venous Thrombosis Mechanisms
  3. Pulmonary Embolism Consequences
  4. Deep Vein Thrombosis Diagnosis
  5. Clinical Forms and Thrombosis Sites
  6. Transient Etiological Risk Factors
  7. Facteurs permanents et enquête étiologique
  8. Recherche étiologique de la MVTE
  9. Facteurs de risque et causes de thrombose
  10. Thrombophilies constitutionnelles
  11. Complications de la thrombose veineuse
  12. Pulmonary Scintigraphy and Echocardiography
  13. Pulmonary Embolism Severity
  14. Recurrence and Postphlebitic Syndrome
  15. Curative Anticoagulant Treatment
  16. Thrombolysis and Bleeding Risk
  17. Treatment Duration by Thrombosis Type
  18. Pulmonary Embolism Treatment
  19. Additional and Preventive Measures

1. Definition and Clinical Significance

Key Concepts & Definitions

  • Venous thrombosis: Partial or complete venous obstruction by an intraluminal thrombus formed when blood coagulates in a vein.
  • Venous thromboembolic disease: Comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), a potentially immediately life-threatening consequence of DVT.

Essential Points

  • VTE is a frequent and serious condition with an average annual incidence greater than 1 per 1,000 person-years.

  • VTE threatens life in the short term through pulmonary embolism and can cause post-thrombotic syndrome in the long term.

Memory Hook

DVT forms the clot; PE obstructs pulmonary arteries.

2. Venous Thrombosis Mechanisms

★ Must-know

  • Virchow’s triad comprises slowed blood flow (stasis), damage to the vessel wall, and altered hemostasis (hypercoagulability or thrombophilia). - Rudolph Virchow

  • Venous stasis may result from: bed rest, prolonged immobilization, chronic venous insufficiency, external compression by lymph nodes, external compression by digestive or pelvic cancers

  • Thrombin converts circulating fibrinogen into insoluble fibrin, which combines with red blood cells and platelets to form a thrombus.

  • Venous thrombi consist mainly of fibrin and red blood cells, with variable amounts of platelets and leukocytes, and preferentially form at venous valves where low-velocity rotational flow promotes stasis.

Further detail

  • Stasis can cause local hypoxia and endothelial injury, promoting platelet and leukocyte adhesion and thrombosis; vasculitis can injure endothelium even without stasis.
  • Coagulation reactions activate zymogens including factors XII, XI, IX, and II, generating thrombin in enzymatic complexes containing calcium and phospholipids.

  • Activated factors V and VIII amplify thrombin generation, while thrombin also activates the protein C–protein S–thrombomodulin system, which inactivates factors Va and VIIIa.

  • Antithrombin, a liver-synthesized glycoprotein and the principal physiological coagulation inhibitor, acts mainly on thrombin and also on factors Xa, IXa, XIa, and XIIa; it is required for heparin’s anticoagulant activity.

  • Protein C is a liver-synthesized, vitamin K-dependent inhibitor that circulates inactive, is activated by the thrombin–thrombomodulin complex, and inactivates factors Va and VIIIa when activated.

  • Protein S is a liver-synthesized, vitamin K-dependent glycoprotein that acts as a cofactor for activated protein C, helping it bind phospholipids and inactivate factors Va and VIIIa.

  • Inherited deficiency of antithrombin, protein C, or protein S, or an abnormality that accelerates thrombin generation, can cause or increase the risk of thrombosis.

  • A venous thrombus grows toward the center of the lumen in successive layers of fibrin and red blood cells separated by thin platelet deposits called lines of Zahn.

  • After complete venous occlusion, absent flow can rapidly extend the thrombus upstream and downstream; initially, its upper end may float freely and cause pulmonary embolism, while later retraction and wall thickening can destroy valve function and cause post-thrombotic disease.

3. Pulmonary Embolism Consequences

★ Must-know

  • Most fibrin-rich, red-cell-rich pulmonary emboli originate in the deep veins of the lower limbs.

  • Pulmonary vascular obstruction raises pulmonary artery pressure and right ventricular afterload, causing right ventricular dilation, increased workload, and increased oxygen consumption.

  • Right ventricular ischemia can result from compression of subepicardial coronary vessels and reduced contractility; right ventricular compression of the left ventricle then reduces left ventricular preload, causing low cardiac output, hypotension, and shock.

Further detail

  • Hemodynamic effects are observed when at least 50–60% of the pulmonary vascular bed is obstructed or when emboli recur, and depend on embolism severity and pre-existing cardiovascular status.

  • Pulmonary embolism initially creates dead-space effect in ventilated but unperfused regions, then reduced ventilation in embolized regions and blood-flow redistribution create a shunt effect with a reduced ventilation–perfusion ratio.

  • Hypoxemia in pulmonary embolism is mainly due to shunt effect or, in severe embolism, reduced venous return secondary to decreased cardiac output.

Memory Hook

Obstruction → right-heart strain → reduced left-heart filling → shock.

4. Deep Vein Thrombosis Diagnosis

★ Must-know

📌 Proximal DVT is located above the popliteal region in the popliteal, femoral, iliac, or caval veins, whereas distal DVT is below the popliteal region in the anterior or posterior tibial, peroneal, or soleal veins.

  • DVT clinical signs are inconsistent and nonspecific, so examination should compare both limbs and clinical findings alone cannot establish the diagnosis.

  • The Wells score assigns points for: active cancer, recent lower-limb paralysis, paresis, or plaster immobilization, bed rest over 3 days or major surgery within 12 weeks, pain along a deep vein, whole-leg swelling, calf circumference over 3 cm greater than the other side, pitting edema confined to the symptomatic leg, non-varicose collateral veins, documented previous DVT, an alternative diagnosis at least as likely as DVT subtracts 2 points

  • Venous ultrasound with Doppler is the reference test for confirming DVT and is painless, repeatable, and feasible at the bedside.

Further detail

  • DVT may cause pain along a vein, in the calf, groin, or thigh; calf pain may be spontaneous or provoked by palpation or foot dorsiflexion.

  • Homans’ sign is present in 60% of cases but has low sensitivity and specificity for DVT.

  • DVT may cause firm edema that pits little or not at all, local warmth, and superficial collateral venous dilation; edema location varies with thrombus location and may extend from the calf to the groin.

  • The initial Wells DVT score indicates low probability at 0 or below, intermediate probability at 1–2, and high probability at 3 or above.

  • Ultrasound signs of DVT include: a visible fixed, wall-adherent intraluminal thrombus, a visible mobile intraluminal thrombus, venous incompressibility, reduced or absent Doppler signal, partial or absent color filling

  • With suitable high-resolution equipment and an experienced operator, venous Doppler ultrasound has sensitivity and specificity of approximately 95%.

  • D-dimers are products of fibrin degradation after formation and lysis of an evolving thrombus; a negative result has a 95% negative predictive value and makes DVT very unlikely.

  • The recommended D-dimer threshold is below 500 ng/mL for people under 50 years and is adjusted to age multiplied by 10 above 50 years; for example, the threshold at age 78 is 780 μg/L.

  • D-dimer levels can rise in: age, pregnancy, the neonatal period, postoperative state, and black populations, VTE, myocardial ischemia, peripheral arterial disease, heart failure, and atrial fibrillation, aortic dissection, stroke, thrombolysis, cancer, and infection, recent trauma, hemorrhage, hemolysis, and disseminated intravascular coagulation, renal or hepatic failure, hospitalization, and bed rest

  • The differential diagnosis of a painful swollen leg includes: ruptured Baker’s cyst, sciatica, hematoma, muscle tear or localized myositis, tendinitis, venous compression by lymph nodes or pelvic tumor, lymphedema, post-thrombotic syndrome, erysipelas, lymphangitis, or inflammatory cellulitis, chronic venous insufficiency or varicosities

5. Clinical Forms and Thrombosis Sites

★ Must-know

  • Phlegmasia coerulea dolens is a highly obstructive DVT with severe inflammation and edema that can compress and slow arterial flow, causing a cold, cyanotic limb with absent pulses; it is a vascular emergency requiring anticoagulation and urgent thrombectomy or decompressive fasciotomy.

  • Superficial venous thrombosis has lower embolic risk than DVT, but risk is present when the thrombus is extensive or near the great saphenous junction, and it can coexist with or progress to DVT or PE.

  • Pregnancy increases thrombotic risk, DVT symptoms can be difficult to interpret in pregnancy, and D-dimer testing has limited usefulness; Doppler ultrasound can confirm the diagnosis without danger to the fetus.

Further detail

  • Upper-limb superficial venous thrombosis commonly follows venous catheter placement, intravenous contrast injection, or trauma; lower-limb superficial thrombosis often occurs in women with varicose veins and commonly affects the great saphenous vein.

  • Upper-limb DVT typically causes rapidly developing painful swelling that begins on the back of the hand and progresses to the inner arm and axilla, followed by collateral veins over the shoulder and anterior chest.

  • Causes of upper-limb DVT include: intravascular devices, cancer or tumor compression, local trauma or shoulder surgery, ovarian hyperstimulation syndrome, effort-related thrombosis (Paget–Schroetter syndrome), venous thoracic outlet compression, idiopathic cases

  • Inferior vena cava thrombosis may extend from an iliac or renal vein thrombus, cause bilateral or alternating leg signs and abdominal superficial collateral veins, and may be detected only by imaging because it is usually non-obstructive.

  • Superior vena cava thrombosis is commonly associated with deep cancer or a catheter and can cause progressive dyspnea, cough, jugular venous distension, cape-like edema, supraclavicular fullness, chest-wall collateral veins, or laryngeal edema; chest CT angiography confirms the diagnosis.

  • Pelvic venous thrombosis occurs with abdominopelvic surgery, pregnancy, or postpartum and may cause uterovaginal pain, urinary symptoms, dysuria, rectal tenesmus, subocclusive symptoms, or fever; diagnosis is difficult because pelvic veins may extend into the deep iliac network.

  • Renal vein thrombosis may cause acute abdominal or lumbar pain, hematuria, proteinuria, a palpable kidney, or no symptoms, and may be diagnosed by Doppler ultrasound or CT.

  • Digestive venous thromboses include: portal vein thrombosis, mesenteric vein thrombosis, hepatic vein thrombosis (Budd–Chiari syndrome)

  • Cerebral venous thrombosis is occlusion of dural sinuses or superficial or deep cerebral veins; it is rare and serious, may present with intracranial hypertension, and is diagnosed by cerebral CT angiography or MR angiography.

6. Transient Etiological Risk Factors

Essential Points

📌 Etiological investigation of VTE must not delay anticoagulant treatment and is needed to determine treatment duration and identify previously unrecognized disease such as cancer or antiphospholipid syndrome.

📌 VTE risk factors are classified as transient provoking events or permanent patient-related factors, and multiple factors can coexist and interact additively.

  • Transient VTE risk factors include: orthopedic, major abdominal, knee arthroscopic, or neurosurgery, fractures, contusions, or sprains, pregnancy, delivery, cesarean section, postpartum, or abortion, prolonged bed rest, paralysis, plaster immobilization, prolonged travel

7. Facteurs permanents et enquête étiologique

Essential Points

  • Les facteurs permanents liés au patient sont: âge, thrombophilies constitutionnelles, thrombophilies acquises, antécédents de MVTE, cancer évolutif, leucémie ou syndrome myéloprolifératif, maladies inflammatoires et infections chroniques, médicaments, maladies cardiovasculaires, insuffisance veineuse chronique et compression veineuse, obésité

8. Recherche étiologique de la MVTE

★ Must-know

  • L’enquête étiologique de la MVTE ne doit jamais retarder la mise en route du traitement anticoagulant, mais elle est nécessaire pour préciser sa durée et dépister des pathologies méconnues, notamment un cancer ou un SAPL.

  • La MVTE est multifactorielle : les facteurs transitoires correspondent aux événements déclenchants, tandis que les facteurs permanents sont propres au patient ; plusieurs facteurs peuvent coexister et leurs interactions sont additives.

Further detail

  • L’enquête étiologique comprend l’anamnèse, l’examen physique et des examens complémentaires choisis selon la présentation clinique.

  • L’anamnèse recherche notamment l’âge, la profession, les médicaments, un voyage récent, une immobilisation, une chirurgie ou un traumatisme récents, une grossesse ou un post-partum, des antécédents personnels ou familiaux de MVTE ou de thrombophilie, une connectivite ou vascularite, un cancer, une maladie inflammatoire ou infectieuse chronique et une insuffisance cardiaque ou respiratoire chronique.

  • L’examen physique recherche: obésité ou paralysie d’un membre inférieur, maladie post-phlébitique ou varices des membres inférieurs, lésions cutanées, uvéite ou vascularite, adénopathies, organomégalie ou masses abdominales ou pelviennes, touchers pelviens et examen des seins systématiques

  • Le bilan complémentaire, adapté au contexte, peut comprendre NFS, VS, CRP, électrophorèse des protides, bilan hépatique, recherche d’hématurie ou de protéinurie et radiographie thoracique, systématique surtout chez les personnes tabagiques.

📌 Les anticorps antinucléaires, les antiphospholipides, le bilan de thrombophilie constitutionnelle et la recherche d’hyperhomocystéinémie sont demandés selon le contexte, en particulier avant ou à l’âge de 45 ans et en cas d’antécédents personnels ou familiaux de MVTE.

  • Les explorations tumorales, dont endoscopies digestives, mammographie, frottis cervico-vaginal, imagerie abdominale ou pelvienne, marqueurs tumoraux et gestes invasifs, sont choisies selon les éléments cliniques et paracliniques.

📌 Un test pathergique et un examen ophtalmologique sont demandés si des signes orientent vers une maladie de Behçet, tandis qu’une cytométrie de flux est envisagée en cas de thrombose digestive ou d’anomalies de l’hémogramme évoquant une hémoglobinurie paroxystique nocturne.

Memory Hook

Interroger, examiner, puis explorer.

9. Facteurs de risque et causes de thrombose

Key Concepts & Definitions

  • Syndrome des antiphospholipides: Associe des manifestations cliniques telles que des thromboses veineuses ou artérielles et des fausses couches à répétition à la présence d’anticorps antiphospholipides, parfois avec thrombopénie.

★ Must-know

  • Dans 30 % des cas de thrombose veineuse, l’enquête étiologique peut rester négative et une surveillance est alors nécessaire.

  • Le risque de MVTE augmente avec l’âge et double à chaque décennie après 40 ans.

  • Les voyages prolongés avec plus de 6 heures en position assise, l’alitement prolongé, l’immobilisation plâtrée, la chirurgie récente, la grossesse et le post-partum sont des facteurs de risque transitoires dont la recherche aide à limiter les récidives.

  • À âge égal, la grossesse multiplie par 5 le risque de TVP ; 80 % des événements surviennent après la 28e semaine et surtout en post-partum, et la TVP est la première cause de morbi-mortalité chez la femme enceinte.

  • Dans le cancer, la thrombose peut résulter d’une hypercoagulabilité, d’une altération de la paroi vasculaire ou d’une stase.

📌 La survenue d’une TIH impose l’arrêt de l’héparine et une surveillance des plaquettes avant traitement, à J2 et J5, puis deux fois par semaine.

Further detail

  • Les antécédents de thrombose veineuse, l’obésité, l’insuffisance veineuse et les varices des membres inférieurs sont des facteurs de risque de MVTE.

  • Les principaux facteurs prédictifs de TVP en milieu chirurgical sont:

    • âge supérieur à 40 ans
    • alitement de plus de 5 jours
    • antécédents de MVTE
    • chirurgie orthopédique
    • chirurgie carcinologique
  • Les cancers du pancréas et de l’estomac figurent parmi les cancers souvent révélés par une TVP, mais presque tous les cancers peuvent être associés à une thrombose.

  • Une thrombose associée au cancer peut survenir chez un patient dont le cancer est connu ou révéler le cancer ; les TVP cancéreuses peuvent être récidivantes et de localisation atypique.

  • Les anticorps antiphospholipides peuvent cibler des phospholipides, notamment la cardiolipine et la phosphatidylsérine, ou des protéines cofacteurs telles que la β2-glycoprotéine 1, la prothrombine et l’annexine V, ainsi que des complexes phospholipidoprotéiques.

  • Les anticorps antiphospholipides peuvent se manifester comme anticoagulant lupique, qui allonge le TCA in vitro, ou comme anticardiolipine ou anti-β2GPI ; ils sont généralement détectés par ELISA.

📌 Le SAPL est primaire lorsqu’il est isolé et secondaire lorsqu’il est associé à un lupus érythémateux systémique ou à une autre maladie auto-immune.

📌 Le syndrome néphrotique se complique souvent de thrombose veineuse, notamment des veines rénales, surtout en cas de glomérulonéphrite extramembraneuse ou d’albuminémie inférieure à 20 g/L.

  • Dans le lupus érythémateux systémique, le risque thrombotique est surtout lié aux anticorps antiphospholipides et aux anticoagulants lupiques, mais une thrombose reste possible sans SAPL.

Memory Hook

Cancer → hypercoagulabilité, atteinte vasculaire ou stase → thrombose.

10. Thrombophilies constitutionnelles

★ Must-know

  • Un déficit en antithrombine est associé à un risque de thrombose multiplié par 10 à 50, et plus de 50 % des porteurs présentent un épisode thrombotique avant 30 ans.

  • Dans un plasma normal, l’ajout de protéine C activée allonge le TCa, tandis qu’en cas de résistance à la protéine C activée, le TCa demeure inchangé.

  • La résistance à la protéine C activée est l’anomalie constitutionnelle la plus fréquente associée à la thrombose et est due à une mutation du facteur V dite mutation Leiden, qui empêche son inactivation physiologique par la protéine C activée.

📌 Un bilan de thrombophilie constitutionnelle est suggéré après une première TVP proximale ou EP non provoquée avant 50 ans avec antécédent familial au premier degré, après un événement veineux récidivant répondant aux critères précisés, ou en cas de thrombose non provoquée d’un site atypique splanchnique, du membre supérieur ou cérébral.

Further detail

  • Les déficits en antithrombine, protéines C ou S et la résistance à la protéine C activée se transmettent sur un mode autosomique dominant et peuvent expliquer une thrombophilie familiale.

📌 Le dosage de l’antithrombine doit être réalisé avant l’héparine, tandis que les dosages des protéines C et S doivent être réalisés avant les AVK.

  • Un déficit en protéine C, plus rarement en protéine S, peut se révéler par des nécroses cutanées au début d’un traitement par AVK, complication prévenue par une introduction progressive des AVK lorsque le déficit est connu.

  • La mutation G20210A du gène de la prothrombine augmente le potentiel thrombotique.

  • L’hyperhomocystéinémie est un facteur de risque de MVTE et d’athérosclérose précoce ; sa recherche est indiquée dans le bilan de thrombophilie en cas de thrombose de localisation atypique.

  • L’homocystinurie est une maladie génétique rare due à un déficit en cystathionine bêta-synthase, qui entraîne une accumulation d’homocystéine et de méthionine et associe ectopie cristallinienne, thromboses vasculaires, ostéoporose et anomalies neurologiques.

📌 Lorsqu’il est indiqué, le bilan spécialisé recherche les déficits en antithrombine, protéines C et S, ainsi que les mutations Leiden du facteur V et G20210A du facteur II, entre le troisième et le sixième mois après le diagnostic de thrombose.

Memory Hook

Le déficit en antithrombine augmente le risque ; la résistance à la protéine C activée empêche son effet anticoagulant.

11. Complications de la thrombose veineuse

★ Must-know

  • À court terme, le pronostic vital d’une TVP dépend du risque d’embolie pulmonaire ou d’extension ; à long terme, il dépend du risque de récidive, tandis que le pronostic fonctionnel est lié au syndrome post-phlébitique.

  • L’embolie pulmonaire est la complication majeure de la thrombose veineuse et doit être recherchée systématiquement.

  • 🔄 La démarche diagnostique comporte trois étapes:
    1. suspecter le diagnostic d’embolie pulmonaire
    2. établir une probabilité clinique d’embolie pulmonaire
    3. prescrire un examen diagnostique

📌 En l’absence d’instabilité hémodynamique, toute suspicion d’embolie pulmonaire justifie une estimation formalisée de la probabilité clinique à l’aide d’un score validé, comme le score de Wells simplifié.

  • Le score de Wells simplifié pour l’EP attribue un point à chacun des éléments suivants : antécédent de MVTE, chirurgie ou immobilisation récente au cours du mois précédent, cancer actif, fréquence cardiaque supérieure à 100/min, signes cliniques de TVP, diagnostic alternatif moins probable que l’EP et hémoptysie ; un score supérieur à 1 indique une EP probable et un score inférieur ou égal à 1 une EP improbable.

  • L’angioscanner thoracique multibarette est l’examen de référence pour confirmer l’EP et précise son siège ainsi que ses retentissements pulmonaire et cardiaque.

Further detail

  • Une extension sous anticoagulation peut survenir en cas de sous-dosage ou de résistance à l’héparine liée notamment à un déficit en antithrombine ou à une TIH.

  • Une TVP distale peut s’étendre au territoire proximal ; une TVP proximale peut s’étendre à la veine cave inférieure ou se bilatéraliser.

📌 Une extension sous anticoagulation à dose efficace impose de rechercher une étiologie sous-jacente, telle qu’une néoplasie.

  • Les manifestations possibles de l’embolie pulmonaire sont:

    • douleur thoracique de type pleural
    • dyspnée souvent brutale et inexpliquée
    • état de choc
    • expectorations hémoptoïques
    • toux sèche
    • fébricule
    • syncope
  • L’examen clinique peut montrer une tachypnée dans 70 % des cas, une tachycardie, des signes de TVP ou d’insuffisance cardiaque droite, des râles crépitants unilatéraux ou un éclat de B2 au foyer pulmonaire.

  • La radiographie thoracique, l’ECG et les gaz du sang ne sont ni sensibles ni spécifiques pour l’embolie pulmonaire ; la radiographie et l’ECG aident surtout à éliminer des diagnostics alternatifs, tandis que les gaz du sang évaluent la sévérité respiratoire.

  • La radiographie thoracique peut être normale ou montrer une atélectasie en bande, un épanchement pleural, une coupole diaphragmatique ascensionnée ou un infarctus pulmonaire ; ses diagnostics différentiels comprennent la pneumonie, le pneumothorax et une fracture de côte.

  • L’ECG peut être normal ; la tachycardie est le signe le plus fréquent, tandis que les signes droits S1Q3, bloc de branche droit ou déviation axiale droite sont rares et non spécifiques, et des troubles de repolarisation de V1 à V3 ou des arythmies peuvent aussi être présents.

  • Les gaz du sang peuvent être normaux ou montrer une hypoxémie et une hypocapnie non spécifiques ; une acidose respiratoire avec hypercapnie est un signe de gravité évoquant l’épuisement respiratoire.

  • Une embolie pulmonaire touchant plus de 50 % du lit artériel pulmonaire est un signe de gravité scanographique ; la dilatation des cavités droites et le septum paradoxal indiquent une dysfonction ventriculaire droite et un cœur pulmonaire aigu.

Memory Hook

Suspecter l’EP → estimer sa probabilité → confirmer par un examen.

12. Pulmonary Scintigraphy and Echocardiography

★ Must-know

  • Pulmonary ventilation/perfusion scintigraphy is sensitive, delivers low radiation, carries no allergy risk, and is poorly specific; normal perfusion excludes pulmonary embolism.

  • Indirect echocardiographic signs include:

    • right-chamber dilation without hypertrophy
    • right-ventricular systolic dysfunction
    • pulmonary arterial hypertension
    • tricuspid regurgitation
    • pulmonary-artery dilation
    • inferior vena cava dilation
    • paradoxical interventricular septal motion

Further detail

  • With associated pulmonary disease, ventilation/perfusion scintigraphy is much more often indeterminate.

  • Ventilation/perfusion scintigraphy is used when CT pulmonary angiography is contraindicated and/or according to hospital availability.

  • Transthoracic echocardiography rarely confirms pulmonary embolism directly by showing a thrombus in the pulmonary artery.

  • In cardiogenic shock, echocardiography can assess left-ventricular impact, including a markedly reduced cardiac output and cardiac index.

Memory Hook

A normal perfusion scan excludes PE; echocardiography mainly reveals indirect right-heart strain.

13. Pulmonary Embolism Severity

★ Must-know

  • Four elements assess severity:
    • hemodynamic instability
    • right-ventricular dysfunction
    • myocardial ischemia indicated by increased troponins
    • the simplified PESI score

📌 Hemodynamic instability includes cardiac arrest requiring resuscitation, obstructive shock, or persistent hypotension.

📌 Obstructive shock is defined by systolic blood pressure below 90 mmHg or the need for vasopressors to maintain blood pressure at least 90 mmHg despite fluid resuscitation, together with organ injury from hypoperfusion.

  • The six one-point criteria are:
    • age over 80 years
    • cancer
    • chronic heart failure or chronic respiratory disease
    • heart rate at least 110/min
    • systolic blood pressure below 100 mmHg
    • oxygen saturation below 90%

📌 High-risk pulmonary embolism has mortality above 15% and is complicated by hemodynamic instability; non-high-risk pulmonary embolism has no clinical hemodynamic instability and is subdivided into intermediate and low risk.

📌 Intermediate-risk pulmonary embolism has mortality between 3% and 15% and a simplified PESI score of at least 1 with right-ventricular dysfunction and/or elevated troponins.

Further detail

📌 Persistent hypotension is systolic blood pressure below 90 mmHg or a systolic fall of at least 40 mmHg lasting more than 15 minutes, not caused by recent arrhythmia, hypovolemia, or sepsis.

  • Right-ventricular dysfunction can be detected by echocardiography as right-ventricular dilation, systolic dysfunction, or pulmonary hypertension, and by CT pulmonary angiography as right-ventricular dilation.

  • A simplified PESI score of 0 corresponds to low mortality risk of 1%, whereas a score of 1 or more corresponds to high risk of 10.9%.

  • Low-risk pulmonary embolism has mortality below 1%.

14. Recurrence and Postphlebitic Syndrome

Key Concepts & Definitions

  • Postphlebitic syndrome: A complication attributed to destruction of venous valves and damage to the venous wall by pre-thrombotic distension.

★ Must-know

📌 Recurrent deep-vein thrombosis requires investigation for an underlying cause, often thrombophilia in a young person and malignancy in an older person.

Further detail

  • Recurrence assessment considers:

    • sex
    • whether the event was provoked
    • pulmonary-embolism mortality risk
    • persistence of an underlying cause
    • age
    • BMI
    • D-dimer levels during follow-up
    • signs of postphlebitic syndrome
  • The last four listed recurrence factors—age, BMI, D-dimer levels during follow-up, and signs of postphlebitic syndrome—are components of the HERDOO2 score used to assess recurrence risk after anticoagulant cessation in women.

  • Postphlebitic syndrome causes lower-limb pain and edema that worsen on standing, with trophic changes that can include cutaneous hyperkeratosis, ochre dermatitis, and depigmentation.

  • A venous leg ulcer is the most feared complication of postphlebitic syndrome.

Memory Hook

Valve destruction and venous-wall damage → dependent pain, edema, and trophic skin changes.

15. Curative Anticoagulant Treatment

★ Must-know

  • Curative treatment aims to limit venous-thrombosis extension and reduce pulmonary-embolism and early-recurrence risks.

  • Initial unfractionated-heparin dosing is 500 IU/kg/day intravenously or subcutaneously, and is adjusted to a patient-to-control aPTT ratio of 1.5–2.5.

  • Low-molecular-weight heparins are administered subcutaneously in fixed weight-based doses, usually once or twice daily, and routine anti-Xa monitoring does not improve efficacy or safety.

📌 Low-molecular-weight heparins are contraindicated when creatinine clearance is below 30 mL/min, and clearance should be assessed especially in older patients because of accumulation risk.

  • Vitamin K antagonists are started early, from day 1, while heparin is continued until the INR reaches the therapeutic range of 2–3.

📌 Direct oral anticoagulants directly inhibit activated coagulation factors, whereas vitamin K antagonists indirectly inhibit vitamin-K-dependent factors.

Further detail

  • The pretreatment assessment includes: blood group, creatinine with calculated creatinine clearance, blood count with platelets, prothrombin time, activated partial thromboplastin time

  • Absolute contraindications include: overt bleeding, recent hemorrhagic stroke, recent neuromedullary surgery, severe head trauma, platelet count below 50,000 G/L, previous heparin-induced thrombocytopenia for heparin use, severe hemostatic disorder

  • Relative contraindications include:

    • recent surgery
    • brain tumor
    • recent gastrointestinal bleeding
    • active peptic ulcer
    • macroscopic hematuria
    • uncontrolled severe hypertension
  • Intravenous unfractionated heparin is generally started with a 100 IU/kg bolus, followed by continuous infusion or intermittent intravenous administration every 4 hours.

  • With continuous intravenous unfractionated heparin, check aPTT 4 hours after treatment begins; with intermittent administration, check it midway between the second and third injections.

  • Unfractionated heparin is recommended when low-molecular-weight heparin is contraindicated and is useful when anticoagulation may need urgent interruption because its half-life is short.

📌 Platelet counts must be monitored twice weekly during treatment with any heparin because of the risk of heparin-induced thrombocytopenia.

  • Examples of twice-daily regimens are:

    • dalteparin 100 IU/kg every 12 hours
    • nadroparin 85 IU/kg every 12 hours
    • enoxaparin 100 IU/kg every 12 hours
  • Examples of once-daily low-molecular-weight-heparin doses are nadroparin 171 IU/kg every 24 hours and tinzaparin 175 IU/kg every 24 hours.

  • Check the INR 72 hours after starting a vitamin K antagonist.

Memory Hook

Heparins act promptly; vitamin K antagonists act slowly and require INR monitoring.

16. Thrombolysis and Bleeding Risk

★ Must-know

📌 Anticoagulants prevent thrombus extension and migration, whereas fibrinolytics lyse the thrombus but carry a much higher bleeding risk.

📌 Unless an absolute contraindication is present, fibrinolysis should be used for pulmonary embolism with shock and is added to anticoagulation without changing its duration or intensity.

Further detail

  • For acute pulmonary embolism, fibrinolysis restores pulmonary perfusion faster than unfractionated heparin alone and can reduce pulmonary arterial pressure and resistance while improving right-ventricular function.

  • Streptokinase regimens are a 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for 12–24 hours, or an accelerated 1,500,000 IU dose over 2 hours.

  • Alteplase (rt-PA) is given as 100 mg over 2 hours or 0.6 mg/kg over 15 minutes, up to a maximum of 50 mg.

  • Absolute contraindications are:

    • active bleeding
    • ischemic stroke within the previous 2 months
    • intracranial hemorrhage
  • Relative contraindications include: major surgery, childbirth, deep biopsy, or puncture of a non-compressible vessel within 10 days, trauma within 15 days, neurosurgery or ophthalmic surgery within 1 month, severe hypertension above 180 mmHg systolic or 120 mmHg diastolic, prolonged cardiac massage, platelet count below 100,000, pregnancy, endocarditis, proliferative diabetic retinopathy

Memory Hook

Anticoagulants limit clot extension; fibrinolytics actively lyse the thrombus.

17. Treatment Duration by Thrombosis Type

★ Must-know

  • Anticoagulation duration is determined by balancing recurrence risk assessed with HERDOO2 against bleeding risk assessed with VTE-BLEED.
  • Direct oral anticoagulants are the current treatment of choice for proximal deep-vein thrombosis, with duration determined by thrombotic risk factors and bleeding and recurrence risks.

📌 Distal deep-vein thrombosis is treated with anticoagulation for 3 months, with longer treatment when it occurs in the context of active cancer.

📌 Recurrent venous thrombosis requires treatment beyond 3 months; recurrence despite an adequate anticoagulant dose may prompt a drug switch, a therapeutic-dose increase of low-molecular-weight heparin or a direct oral anticoagulant, or vitamin K antagonists with a higher INR target.

Further detail

  • The VTE-BLEED score assigns 2 points for active cancer and 1 point for uncontrolled hypertension in men; anemia, previous bleeding, creatinine clearance of 30–60 mL/min, and age at least 60 years each score 1.5 points.
  • Direct oral anticoagulant superiority has not been established for superficial venous thrombosis, whose treatment duration depends on thrombus extent, proximity to the deep-vein junction, and persistent thrombotic risk factors.

📌 Removal of incompetent superficial veins should be considered at least 3 months after the acute inflammatory and prothrombotic phase.

📌 Upper-limb deep-vein thrombosis without a thrombotic risk factor is treated for 3 months.

  • For catheter-associated deep-vein thrombosis, anticoagulation with low-molecular-weight heparin or low-molecular-weight heparin followed by a vitamin K antagonist is given for at least 3 months, and catheter removal may be considered.

  • Pregnancy-associated deep-vein thrombosis is treated with therapeutic-dose low-molecular-weight heparin for at least 3 months and at least 6 weeks after delivery.

  • Cancer-associated deep-vein thrombosis is treated with low-molecular-weight heparin for at least 3–6 months; direct oral anticoagulants are also treatment options but require caution in gastrointestinal and genitourinary cancers because of increased bleeding risk, particularly with active mucosal lesions.

  • Prolonged anticoagulation is used for thrombophilia, vitamin K antagonists are preferred in antiphospholipid syndrome, and low-molecular-weight-heparin and direct oral anticoagulant doses are reduced in renal impairment.

18. Pulmonary Embolism Treatment

★ Must-know

  • Treatment of stable pulmonary embolism follows that of proximal deep-vein thrombosis, whereas severe or unstable pulmonary embolism is managed using an unfractionated-heparin-to-vitamin-K-antagonist or direct-oral-anticoagulant regimen.

📌 For cancer-associated venous thromboembolism, anticoagulation is continued while the cancer remains active and the treatment benefit-risk balance remains favorable.

📌 Severe, high-risk pulmonary embolism requires fibrinolysis and management in intensive care or a critical-care unit.

Further detail

  • Unfractionated heparin followed by a vitamin K antagonist is reserved for severe or unstable pulmonary embolism, severe renal impairment, or particular bleeding risk; a direct oral anticoagulant may be used for the relay when not contraindicated.

  • Low-molecular-weight heparin without vitamin K antagonist relay is classically used for cancer-associated pulmonary embolism and pregnancy.

  • Pulmonary embolism provoked by a major transient risk factor such as surgery or limb trauma is treated for 3 months because recurrence risk after stopping is very low.

  • Idiopathic pulmonary embolism is treated for at least 6 months, and recurrent idiopathic pulmonary embolism requires prolonged treatment.

  • Pulmonary embolism associated with chronic cor pulmonale, reported in 3% of pulmonary embolisms, requires prolonged treatment because recurrence may be particularly serious in a fragile patient.

19. Additional and Preventive Measures

★ Must-know

  • Venous-thromboembolism prevention includes early ambulation and mobilization, limb elevation, breathing exercises, and elastic compression; prophylactic anticoagulation may be used according to individually assessed thrombosis risk.

Further detail

  • Elastic compression is part of deep-vein-thrombosis treatment, rapidly improves symptoms, and limits post-thrombotic disease risk; elastic bandages can be adjusted more easily when initial edema is present, and class 2 or sometimes class 3 stockings may be used.

  • Compression is worn continuously during the first days and then during the daytime.

  • Bed rest has no role in venous thromboembolism treatment, particularly after anticoagulation has begun.

  • An inferior vena cava filter mechanically prevents embolic migration and is mainly indicated when anticoagulation fails or is contraindicated.

  • Venous thrombectomy is mandatory in phlegmasia cerulea dolens.

  • Low-molecular-weight heparin is a simple and effective prophylactic option, used in surgical settings including postoperative care or prolonged immobilization; direct oral anticoagulants can be used after hip or knee replacement surgery.

  • Medical inpatients who are bedridden and have associated risk factors such as advanced age, marked obesity, leg varicose veins, previous venous thromboembolism, or a known deficiency of physiological coagulation inhibitors warrant consideration of prophylaxis.

  • For tinzaparin prophylaxis, the listed doses are 2,500 IU/day for low risk, 3,500 IU/day for moderate risk, and 4,500 IU/day for high risk; enoxaparin 40 mg/day and dalteparin 5,000 IU/day are also listed.

📌 Prophylaxis generally covers hospitalization or immobilization, and after major orthopedic surgery it is recommended to continue for 6 weeks.

Synthesis Tables

Risk Categories of Pulmonary Embolism

CategoryHemodynamicsMortality / criteria
High riskInstability presentMortality above 15%
Intermediate riskNo clinical instabilityMortality 3–15%; simplified PESI ≥1 with right-ventricular dysfunction and/or elevated troponins
Low riskNo clinical instabilityMortality below 1%

Test yourself

Take a 56-question practice quiz on Venous Thromboembolism Management, with every answer explained.

1. A clot formed inside a vein partially obstructs its lumen. What is this condition called?

2. A patient has a deep vein clot that has led to obstruction of a pulmonary artery by a traveling thrombus. Which condition pair describes this venous thromboembolic disease?

Take the quiz →

Study with flashcards

Memorize the key concepts of Venous Thromboembolism Management with 94 flashcards.

What is venous thrombosis?

Partial or complete venous obstruction by an intraluminal thrombus formed when blood coagulates in a vein.

Which conditions comprise venous thromboembolic disease?

Deep vein thrombosis and pulmonary embolism.

What are the three components of Virchow’s triad, according to Rudolph Virchow?

Stasis, vessel-wall damage, and altered hemostasis.

See the flashcards →

Related classes

Make your own study guides

Upload your class notes and Revizly writes a study guide, a quiz and flashcards in about a minute.

Study guide maker